ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

GLMD Galmed Pharmaceuticals Ltd

0.3916
-0.0009 (-0.23%)
26 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Galmed Pharmaceuticals Ltd GLMD NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
-0.0009 -0.23% 0.3916 17:30:10
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.3949 0.367 0.3949 0.3916 0.3925
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
04/4/202416:06PRNUSGalmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F..
15/3/202408:00PRNUSGalmed Announces Grant of New Patent for the Combination of..
14/2/202413:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202415:15EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
29/11/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
22/11/202315:48EDGAR2Form POS AM - Post-Effective amendments for registration..
20/11/202315:37EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/11/202315:32PRNUSGalmed Announces a delay in the initiation of its Primary..
01/11/202315:15EDGAR2Form POS AM - Post-Effective amendments for registration..
26/9/202307:51EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
26/9/202307:30PRNUSGalmed Announces Allowance of New Patent for Aramchol for..
22/9/202315:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/9/202315:05PRNUSGalmed Pharmaceuticals Announces Receipt of Nasdaq Minimum..
21/9/202306:30EDGAR2Form 6-K/A - Report of foreign issuer [Rules 13a-16 and..
20/9/202315:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/9/202315:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/8/202315:43EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/8/202315:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/8/202315:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/7/202309:12EDGAR2Form SC 13G - Statement of acquisition of beneficial..
18/7/202308:25EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/7/202308:23EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
14/7/202308:44EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/7/202308:30PRNUSGalmed Pharmaceuticals Announces Pricing of $7 Million..
13/7/202316:08EDGAR2Form F-1/A - Registration statement for certain foreign..
12/7/202316:29EDGAR2Form F-1/A - Registration statement for certain foreign..
10/7/202307:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/7/202307:00PRNUSGalmed to employ OnKai's disruptive Artificial Intelligence..
28/6/202307:40EDGAR2Form FWP - Filing under Securities Act Rules 163/433 of free..
28/6/202307:37EDGAR2Form F-1/A - Registration statement for certain foreign..
01/6/202307:00PRNUSGalmed Pharmaceuticals Reports First Quarter 2023 Financial..
09/5/202306:00PRNUSGalmed Announces Initiation of a Clinical Development..

Su Consulta Reciente

Delayed Upgrade Clock